Chimeric Antigen Receptor (CAR) T-Cell Therapy And Cytokine Release Syndrome: Do We Need To Be Innovative To Overcome The CAR T-Cell Associated Toxicities

Abstract

Chimeric antigen receptor (CAR) T -cell therapy is the target specific therapy that utilizes the function of genetically
engineered T -cells in production of artificial T-cell receptors for being utilized as immunotherapy for treating cancers. It’s
not only an exciting revolution in the field of hematology, but also now being utilized in treatment of solid tumors. Despite of
having such an exciting revolution, the use of CAR T-cell therapy is restricted due to its associated toxicities like
cytokine release syndrome (CRS) and neurotoxicity thus posing the dire need of development of new strategies that could
ameliorate the toxic side effects and can provide better target specific therapies like CAR off switches, suicide gene
strategies, modifying the CAR transduced T cells, and altering the affinity of the CAR -T cell’s antigen binding domain.

Keywords: CAR-T cell therapy, Cytokine release syndrome, Toxicity.